Immune globulin - Baxalta

Drug Profile

Immune globulin - Baxalta

Alternative Names: 10% HyQ; 20% SubQ; CuvitruTM; Gammagard Liquid; Gammagard S/D; Human Immune Globulin for Subcutaneous Administration; HyQ; HyQvia; IGIV - Baxalta; IGSC - Baxalta; immune globulin intravenous; IVIG 10%; Kiovig; SCIG 20%

Latest Information Update: 21 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Baxter International
  • Developer Baxter International; Halozyme Therapeutics; Shire
  • Class Immunoglobulins; Immunoproteins; Serum globulins
  • Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Peripheral nervous system diseases; Chronic inflammatory demyelinating polyradiculoneuropathy
  • New Molecular Entity No

Highest Development Phases

  • Marketed Allotransplant rejection; Chronic lymphocytic leukaemia; Guillain-Barre syndrome; HIV infections; Immune thrombocytopenic purpura; Immunodeficiency disorders; Peripheral nervous system diseases
  • Phase III Chronic inflammatory demyelinating polyradiculoneuropathy
  • Phase II Ataxia
  • Suspended Alzheimer's disease

Most Recent Events

  • 03 Mar 2017 Adverse events data from a phase II/III trial in Immunodeficiency disorders presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2017)
  • 03 Mar 2017 Pooled safety data from two paediatric phase II/III trials in Immunodeficiency disorders presented at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2017)
  • 03 Mar 2017 Pooled safety data from two phase II/III trials in Immunodeficiency disorders presented at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top